Cefpodoxime Dry Syrup
Cefpodoxime 50 mg
Cefpodoxime Proxetil Dry Syrup is a cephalosporin antibiotic. It is given as a Cefpodoxime proxetil. Cefpodoxime proxetil is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime It is active against most Gram positive and Gram negative bacteria. It is commonly used to treat acute otitis media, pharyngitis, and sinusitis.
It is Used to Treat Number of Bacterial Infections Including:
- Acute otitis media
- Pharyngitis and/or tonsillitis
- Community-acquired pneumonia
- Acute bacterial exacerbation of chronic bronchitis
- Acute, uncomplicated urethral and cervical gonorrhea
- Acute, uncomplicated ano-rectal infections in women
- Uncomplicated skin and skin structure infection
- Acute maxillary sinusitis
- Uncomplicated urinary tract infections (cystitis).
Mechansium Of Action:
The bactericidal activity of cefpodoxime results from its inhibition of cell wall synthesis. The active metabolite of cefpodoxime binds preferentially to penicillin binding protein 3, which inhibits production of peptidoglycan, the primary constituent of bacterial cell walls. Cefpodoxime proxetil is a prodrug that is absorbed from the gastrointestinal tract and de-esterified to its active metabolite, cefpodoxime.
The Most Commonly Reported Adverse Effects are:
- Upset stomach
- Mild skin rash.
Hypersensitivity reactions to cefpodoxime, other cephalosporins, penicillins, or other drugs.
Contraindicated in Pregnancy and lactation in women, stomach and bleeding disorders.
Antacids: Concomitant administration of high doses of antacids (sodium and aluminum hydroxide) or H2 blockers reduces peak plasma levels by 24% to 42% and the extent of absorption by 27% to 32%, respectively. The rate of absorption is not altered by these concomitant medications. Oral anti-cholinergics (e.g., propantheline) delay peak plasma levels (47% increase in Tmax), but do not affect the extent of absorption (AUC).
Probenecid: As with other beta-lactam antibiotics, renal excretion of cefpodoxime was inhibited by probenecid and resulted in an approximately 31% increase in AUC and 20% increase in peak cefpodoxime plasma levels.
Nephrotoxic Drugs: Although nephrotoxicity has not been noted when cefpodoxime proxetil was given alone, close monitoring of renal function is advised when cefpodoxime proxetil is administered concomitantly with compounds of known nephrotoxic potential.
Drug/Laboratory Test Interactions: Cephalosporins, including cefpodoxime proxetil, are known to occasionally induce a positive direct Coombs' test.